Compare AbbVie Inc (ABBV) vs Cisco Systems Inc (CSCO) Price & Performance

AbbVie (ABBV) trades at $252.92, down 0.72% on the day, with strong technical support at $251 and resistance at $258. The stock shows bullish momentum with recent earnings beats and a consensus analyst price target of $266.33. Revenue grew to $61.16B in 2025, though net margins compressed to 5.79%. Key growth drivers include Skyrizi and Rinvoq offsetting Humira declines, supported by positive Phase 2 data for ELAHERE in ovarian cancer (PRNewsWire, 2026-04-12).

Outlook remains positive with immunology portfolio strength and dividend growth, but risks include patent cliffs in the 2030s and high debt levels. Institutional buying and 68% analyst buy ratings suggest confidence, though valuation multiples like P/E of 124.83 warrant caution. Near-term catalysts include Q2 2026 earnings expected at $3.79 EPS.

Cisco Systems (CSCO) trades at $113.98, up 1.14% on the day, with a technical picture showing bearish momentum indicators but recent positive earnings beats. The company reported Q1 2026 EPS of $1.06, beating expectations of $1.03, continuing a trend of outperformance. Recent news highlights Cisco's strategic push into AI cybersecurity, announcing new software tools and partnerships at Cisco Live 2026. Valuation metrics appear elevated with a P/E of 37.99 and P/S of 7.48, though profitability remains strong with a 64.33% gross margin.

The outlook balances strong analyst support (52% buy ratings with $130.38 consensus target) against high valuation multiples and mixed technical signals. Investment opportunity centers on Cisco's AI infrastructure and cybersecurity positioning, while risks include execution in transitioning growth drivers, competitive pressures, and potential margin compression if revenue growth slows.